SCHEMBL30793750

SCHEMBL30793750

COc1c(C(=O)O)nn2c1CN(C(=O)OC(C)(C)C)CCC2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 1/20 0.39
▸ MEN1 O00255 2/20 0.37
▸ KMT2A Q03164 2/20 0.37
▸ NR1H2 P55055 2/20 0.36
▸ HPGD P15428 1/20 0.35
▸ CKS1B P61024 1/20 0.35
▸ SKP1 P63208 1/20 0.35
▸ SKP2 Q13309 1/20 0.35
▸ ESR2 Q92731 1/20 0.34
▸ PDE4A P27815 1/20 0.34
▸ PDE4B Q07343 1/20 0.34
▸ PDE4C Q08493 1/20 0.34
▸ CYBB P04839 1/20 0.34
▸ NOX5 Q96PH1 1/20 0.34
▸ NOX4 Q9NPH5 1/20 0.34
▸ NOX1 Q9Y5S8 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30793390 0.87 NR1H2 (0.36) ADORA1MEN1KMT2ANR1H2HPGD
SCHEMBL30793157 0.85 ADORA1 (0.44) ADORA1MEN1KMT2ANR1H2HPGD
SCHEMBL25336741 0.85 MEN1 (0.38) ADORA1MEN1KMT2ANR1H2HPGD
SCHEMBL30793677 0.85 MEN1 (0.38) ADORA1MEN1KMT2ANR1H2HPGD
SCHEMBL30793460 0.84 MEN1 (0.38) ADORA1MEN1KMT2ANR1H2HPGD
SCHEMBL25335687 0.84 MEN1 (0.43) ADORA1MEN1KMT2ANR1H2HPGD
SCHEMBL30793341 0.84 MEN1 (0.38) ADORA1MEN1KMT2ANR1H2HPGD
SCHEMBL30793121 0.82 MEN1 (0.39) ADORA1MEN1KMT2ANR1H2HPGD
SCHEMBL30793426 0.82 MEN1 (0.39) ADORA1MEN1KMT2ANR1H2HPGD
SCHEMBL30793364 0.82 CKS1B (0.36) ADORA1MEN1KMT2ANR1H2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS MIRATI THERAPEUTICS INC (US) 2025-12-04 — — US disclosed
EP-4540254-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2025-04-23 — — EP disclosed
WO-2023244604-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS Mirati Therapeutics, Inc. (US) 2023-12-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368649-A1 TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS KRAS, NRAS, HRAS ADORA1 2859/4885MEN1 948/4885KMT2A 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback